Microgestin 1.5/30 side effects by duration, gender and age - a phase IV clinical study of FDA data
Side effects are reported by people who take Microgestin 1.5/30. Common side effects include abdominal pain upper among females and convulsion among males.
The phase IV clinical study is created by eHealthMe based on 159 reports from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
159 people who take Microgestin 1.5/30 and have side effects are studied.
What is Microgestin 1.5/30?
Microgestin 1.5/30 has active ingredients of ethinyl estradiol; norethindrone acetate. It is often used in birth control. eHealthMe is studying from 204 Microgestin 1.5/30 users for its effectiveness, alternative drugs and more.
Number of Microgestin 1.5/30 reports submitted per year:
Microgestin 1.5/30 side effects by time on the drug *:
Microgestin 1.5/30 side effects by gender *:
Microgestin 1.5/30 side effects by age *:
* Approximation only. Some reports may have incomplete information.
Do you take Microgestin 1.5/30?Personalize this study to your gender and age
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How the study uses the data?
The study is based on ethinyl estradiol; norethindrone acetate (the active ingredients of Microgestin 1.5/30) and Microgestin 1.5/30 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.
Alternative drugs to, pros and cons of Microgestin 1.5/30:
- Microgestin 1.5/30 (204 reports)
All Microgestin 1.5/30 side effects from A to Z:a b c d e f g h i j k l m n o p q r s t u v w x y z
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Arthritis in Benazepril Hydrochloride, how severe and when it was recovered? - 2 seconds ago
- Alendronic Acid and Toothaches - 3 seconds ago
- Benicar Hct vs. Tenoretic 100 - 4 seconds ago
- Swollen Tongue in Flonase Allergy Relief, how severe and when it was recovered? - 4 seconds ago
- Enbrel and Accident - 4 seconds ago
- Benicar Hct vs. Magnesium - 6 seconds ago
- Restlessness Aggravated in Tramadol, how severe and when it was recovered? - 8 seconds ago
- Ativan and Coital Bleeding - 9 seconds ago
- Accident and moderna covid vaccine - 14 seconds ago
- Vitamin D3 and Gammagard drug interaction - 14 seconds ago